Attached files

file filename
EX-10.19 - EXHIBIT 10.19 - Medisun Precision Medicine Ltd.ex10_19apg.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):

November 2, 2015 (November 1, 2015)


Accurexa Inc.

 (Exact name of registrant as specified in its charter)



Delaware

000-54907

47-2999657

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)


113 Barksdale

Newark, DE 19711

 (Address, including zip code, of principal executive offices)


Registrant’s telephone number, including area code

(302) 709-1822


N/A

(Former name or former address, if changed since last report.)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 1.01  Entry into a Material Definitive Agreement


On November 1, 2015 (“Effective Date”), Accurexa, Inc. (“Company”) entered into a service agreement (“Agreement”) with the Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (“Yissum”) to develop and supply a polymeric formulation of a combination of carmustine and temozolomide for sustained local administration to a solid tumor (the “Services”).  Under the Agreement the Company will retain ownership of all intellectual property rights that are discovered or developed during the course of the provision of the Services.  Professor Avi Domb of The Hebrew University of Jerusalem will lead the development efforts provided by Yissum.  For a full description, a Form of the Agreement is filed and can be reviewed as an exhibit hereto.


In connection with entering into the Agreement, the Company issues 1,000,000 shares of the Company’s common stock in order to access the technology know-how.  These shares are issued pursuant to Regulation D under the Securities Act of 1933, as amended, are exempt from registration by reason of Section 4(2) of the Securities Act of 1933, as amended (the “Act”), and bear an appropriate restrictive legend.  



Item 9.01  Financial Statement and Exhibits.


(d) Exhibits.


Number

 

Description

10.19

 

Form of Service Agreement, dated November 1, 2015, by and between Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Accurexa Inc.  Filed herewith.



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 

 

ACCUREXA INC.

 

 


Dated: November 2, 2015

 

By:

/s/ George Yu

 

 

 

Name:

George Yu

 

 

Title:

President & CEO